Mutation of human plasminogen kringle 1–5 enhances antiangiogenic action via increased interaction with integrin αvβ3

Po-Chiao Chang; Yu-Jia Chang; Hua-Lin Wu; Chin-Wei Chang; Chung-I. Lin; Wei-Chih Wang; Guey-Yueh Shi

doi:10.1160/TH07-06-0403

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 99(04): 729-738
DOI: 10.1160/TH07-06-0403

Endothelium and Vascular Development

Schattauer GmbH

Mutation of human plasminogen kringle 1–5 enhances antiangiogenic action via increased interaction with integrin α_vβ₃

Po-Chiao Chang

¹Department of Biochemistry and Molecular Biology

²The Institute of Basic Medical Sciences, College of Medicine

,

Yu-Jia Chang

¹Department of Biochemistry and Molecular Biology

,

Hua-Lin Wu

¹Department of Biochemistry and Molecular Biology

³Cardiovascular Research Center, National Cheng Kung University, Tainan, Taiwan

,

Chin-Wei Chang

¹Department of Biochemistry and Molecular Biology

,

Chung-I. Lin

¹Department of Biochemistry and Molecular Biology

,

Wei-Chih Wang

¹Department of Biochemistry and Molecular Biology

,

Guey-Yueh Shi

¹Department of Biochemistry and Molecular Biology

³Cardiovascular Research Center, National Cheng Kung University, Tainan, Taiwan

› Institutsangaben

Abstract

Summary

Angiogenesis plays a primary role in tumor growth and metastasis. Angiostatin, a proteolytic fragment containing the first four kringle domains of human plasminogen, can inhibit angiogenesis. The anti-angiogenic activities of kringle 1–5 (K_1–5) and kringle 5 fragments of plasminogen are greater than angiostatin in inhibiting angiogenesis and angiogenesis-dependent tumor growth. To further optimize kringle fragment anti-angiogenic activities, mutations were created at the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532, at kringle 5, including K_1–5N289A (replacing Asn by Ala at residue 289), K_1–5T346A, K_1–5L532R, K_1–5N289A/T346A, K_1–5T346A/ L532R, K_1–5N289A/L532R, and K_1–5N289A/T346A/L532R. Wild-type and mutant K_1–5 proteins were expressed successfully by the Pichia pastoris expression system. Native K_1–5 from proteolytic cleavage and wild-type K_1–5 have similar activity in inhibiting basic fibroblast growth factor-induced endothelial cell proliferation. Among these mutated proteins, K_1–5N289A/ T346A/L532R exhibited the greatest effect in inhibiting endothelial cell proliferation and in inducing endothelial cell apoptosis. Integrin α_vβ₃-mediated adhesion of K_1–5N289A/ T346A/L532R to endothelial cells was more greatly enhanced when compared to wild type K_1–5. Furthermore, K_1–5N289A/ T346A/L532R was most potent in inhibiting basic fibroblast growth factor-induced angiogenesis in Matrigel assay in vivo. Angiogenesis-dependent tumor growth was inhibited by systemically injected K_1–5N289A/T346A/L532R into mice. These results demonstrate that alteration of glycosylation and Lys binding properties could increase the anti-angiogenic action of K_1–5, possibly via enhanced interaction with integrin α_vβ₃ in endothelial cells.

Keywords

Angiogenesis and inhibitors - endothelial cells - integrins - plasminogen (-fragments)

Volltext

Referenzen

References
1 Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann NY Acad Sci 2000; 902: 249-262.
2 Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
3 Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
4 O’Reilly MS, Holmgren L, Shing Y. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
5 Cao Y, Ji RW, Davidson D. et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996; 15: 29461-29467.
6 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
7 O’Reilly MS, Holmgren L, Chen C. et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692.
8 Ji WR, Castellino FJ, Chang Y. et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998; 12: 1731-1738.
9 Cao R, Wu HL, Veitonmaki N. et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999; 96: 5728-5733.
10 Pirie-Shepherd SR. Role of carbohydrate on angiostatin in the treatment of cancer. J Lab Clin Med 1999; 134: 553-560.
11 Hayes ML, Castellino JF. Carbohydrate of the human plasminogen variants. I. Carbohydrate composition, glycopeptide isolation, and characterization. J Biol Chem 1979; 254: 8768-8771.
12 Davidson DJ, Castellino FJ. Oligosaccharide structures present on asparagine-289 of recombinant human plasminogen expressed in a Chinese hamster ovary cell line. Biochemistry 1991; 30: 625-633.
13 Pirie-Shepherd SR, Stevens RD, Andon NL. et al. Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2. J Biol Chem 1997; 272: 7408-7411.
14 Chang Y, Mochalkin I, McCance SG. et al. Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry 1998; 37: 3258-3271.
15 McCance SG, Menhart N, Castellino FJ. Amino acid residues of the kringle-4 and kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands. J Biol Chem 1994; 269: 32405-32410.
16 Marti D, Schaller J, Ochensberger B. et al. Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for omega-aminocarboxylic acids. Eur J Biochem 1994; 219: 455-462.
17 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096.
18 Wu HL, Chang BI, Wu DH. et al. Interaction of plasminogen and fibrin in plasminogen activation. J Biol Chem 1990; 265: 19658-19664.
19 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
20 Passaniti A, Taylor RM, Pili R. et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519-528.
21 Cao Y, O’Reilly MS, Marshall B. et al. Expression of angiostatin cDNA in a murine fibrosarcoma sup-presses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998; 101: 1055-1063.
22 Zhang XP, Kamata T, Yokoyama K. et al. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J Biol Chem 1998; 273: 7345-7350.
23 Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 2001; 276: 39562-39568.
24 Troyanovsky B, Levchenko T, Mansson G. et al. Angiomotin: an angiostatin binding protein that regu-lates endothelial cell migration and tube formation. J Cell Biol 2001; 152: 1247-1254.
25 Veitonmaki N, Cao R, Wu LH. et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res 2004; 64: 3679-3686.
26 Chen YH, Wu HL, Li C. et al. Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation. Thromb Haemost 2006; 95: 668-677.
27 Dong Z, Kumar R, Yang X. et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88: 801-810.
28 Rudd PM, Woods RJ, Wormald MR. et al. The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator. Biochim Biophys Acta 1995; 1248: 1-10.
29 Tarui T, Akakura N, Majumdar M. et al. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 2006; 95: 524-554.